Effect of Biological Treatment on Fatigue in Psoriasis: A Systematic Review and Meta-Analysis
Fatigue is frequent in patients with psoriasis. Though conventional drugs in general have no effect on fatigue, biological agents have demonstrated beneficial effects in several other chronic inflammatory diseases.
The objective of the present study was to evaluate the effect of biological drugs on fatigue in patients with psoriasis vulgaris.
We conducted a meta-analysis of randomized controlled trials in which anti-interleukin-12/23, anti-interleukin-23, anti-interleukin-17, or anti-tumor necrosis factor-α agents were used for psoriasis vulgaris and fatigue was an outcome measure.
A total of eight randomized controlled trials fulfilled criteria for inclusion in the meta-analysis. The studies used two fatigue reporting scales: the Functional Assessment of Chronic Illness Therapy-Fatigue and the Short Form 36 Health Survey Vitality Subscale. Treatment by biological agents in general compared with placebo led to a significant reduction in fatigue, with a standardized mean difference of − 0.40 (95% confidence interval − 0.46 to − 0.34; p < 0.001).
Biological drugs used for the treatment of psoriasis vulgaris have a consistently small-to-moderate beneficial effect on fatigue independent of the type of drug.
The authors thank senior librarian Elisabeth Hundstad Molland at the Stavanger University, for providing expert help with the PubMed search.
Compliance with Ethical Standards
Inger Marie Skoie received support as a doctoral research fellow from the Western Norway Regional Health Authority (“Helse Vest”), Grant No. 912015.
Conflict of interest
Inger Marie Skoie has received honoraria for participation in advisory boards and/or as a speaker for AbbVie, Janssen, Eli Lilly, Leo Pharma, and Pfizer pharmaceutical companies. Ingvild Dalen and Roald Omdal have no conflicts of interest that are directly relevant to the content of this article.
- 1.Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983–94.Google Scholar
- 2.Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(21):2095–6.Google Scholar
- 3.Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871–881.e1–30.Google Scholar
- 4.Elder JT, Bruce AT, Gudjonsson JE, Johnston A, Stuart PE, Tejasvi T, et al. Molecular dissection of psoriasis: integrating genetics and biology. J Investig Dermatol. 2010;130(5):1213–26.Google Scholar
- 5.Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.Google Scholar
- 6.Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40.Google Scholar
- 7.Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43–53.Google Scholar
- 8.Skoie IM, Dalen I, Ternowitz T, Jonsson G, Kvivik I, Norheim K, et al. Fatigue in psoriasis: a controlled study. Br J Dermatol. 2017;177(2):505–12.Google Scholar
- 9.Verhoeven EW, Kraaimaat FW, van de Kerkhof PC, van Weel C, Duller P, van der Valk PG, et al. Prevalence of physical symptoms of itch, pain and fatigue in patients with skin diseases in general practice. Br J Dermatol. 2007;156(6):1346–9.Google Scholar
- 10.Krupp LB, Pollina DA. Mechanisms and management of fatigue in progressive neurological disorders. Curr Opin Neurol. 1996;9(6):456–60.Google Scholar
- 11.Dantzer R. Cytokine, sickness behavior, and depression. Immunol Allergy Clin N Am. 2009;29(2):247–64.Google Scholar
- 12.Kent S, Bluthe RM, Dantzer R, Hardwick AJ, Kelley KW, Rothwell NJ, et al. Different receptor mechanisms mediate the pyrogenic and behavioral effects of interleukin 1. Proc Natl Acad Sci USA. 1992;89(19):9117–20.Google Scholar
- 13.Reinertsen KV, Grenaker Alnaes GI, Landmark-Hoyvik H, Loge JH, Wist E, Kristensen VN, et al. Fatigued breast cancer survivors and gene polymorphisms in the inflammatory pathway. Brain Behav Immun. 2011;25(7):1376–83.Google Scholar
- 14.Becker K, Kohen R, Lee R, Tanzi P, Zierath D, Cain K, et al. Poststroke fatigue: hints to a biological mechanism. J Stroke Cerebrovasc Dis. 2015;24(3):618–21.Google Scholar
- 15.Norheim KAA, Imgenberg-Kreuz J, Brun JG, Jonsson R, Ng WF, Theander E, Mandl T, Sivils KL, Rönnblom L, Nordmark G, Omdal R. Genetic determinants of fatigue in primary Sjögren’s syndrome: a genome wide association study. 2017 ACR/ARHP Annual Meeting, San Diego, CA. Arthritis Rheumatol. 2017;69(Suppl. 10):2017.Google Scholar
- 16.Braekke Norheim K, Imgenberg-Kreuz J, Jonsdottir K, Janssen EA, Syvanen AC, Sandling JK, et al. Epigenome-wide DNA methylation patterns associated with fatigue in primary Sjogren’s syndrome. Rheumatology (Oxford). 2016;55(6):1074–82.Google Scholar
- 17.Hewlett S, Dures E, Almeida C. Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACIT-F), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS). Arthritis Care Res (Hoboken). 2011;63(Suppl. 11):S263–86.Google Scholar
- 18.Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121–3.Google Scholar
- 19.Wolfe F, Michaud K, Pincus T. Preliminary evaluation of a visual analog function scale for use in rheumatoid arthritis. J Rheumatol. 2005;32(7):1261–6.Google Scholar
- 20.Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manag. 1997;13(2):63–74.Google Scholar
- 21.Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39(3):315–25.Google Scholar
- 22.Belza BL. Comparison of self-reported fatigue in rheumatoid arthritis and controls. J Rheumatol. 1995;22(4):639–43.Google Scholar
- 23.Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.Google Scholar
- 24.Almeida C, Choy EH, Hewlett S, Kirwan JR, Cramp F, Chalder T, et al. Biologic interventions for fatigue in rheumatoid arthritis. Cochrane Database Syst Rev. 2016;6:CD008334.Google Scholar
- 25.Skoie IM, Ternowitz T, Jonsson G, Norheim K, Omdal R. Fatigue in psoriasis: a phenomenon to be explored. Br J Dermatol. 2015;172(5):1196–203.Google Scholar
- 26.Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;1(4):1.Google Scholar
- 27.Valenzuela F, Paul C, Mallbris L, Tan H, Papacharalambous J, Valdez H, et al. Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a phase 3 study. J Eur Acad Dermatol Venereol. 2016;30(10):1753–9.Google Scholar
- 28.Higgins JPT, Green S, Cochrane C. Cochrane handbook for systematic reviews of interventions. S.l. London: The Cochrane Collaboration; 2011.Google Scholar
- 29.Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol. 2010;162(1):137–46.Google Scholar
- 30.Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–31.Google Scholar
- 31.Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol. 2008;159(3):704–10.Google Scholar
- 32.Bradburn MJ, Deeks JJ, Altman DG. Metan: an alternative meta-analysis command. Stata Techn Bull. 1999;44:4–15.Google Scholar
- 33.Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, et al. Impact of adalimumab treatment on patient-reported outcomes: results from a phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatol Treat. 2007;18(6):341–50.Google Scholar
- 34.Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatol Treat. 2007;18(1):25–31.Google Scholar
- 35.Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367(9504):29–35.Google Scholar
- 36.Borenstein M. Introduction to meta-analysis. Chichester: Wiley; 2009.Google Scholar
- 37.Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol. 2006;154(6):1161–8.Google Scholar
- 38.Harris R, Bradburn M, Deeks J, Harbord R, Altman D, Sterne J. Metan: fixed- and random-effects meta-analysis. Stata J. 2008;8(1):3–28.Google Scholar
- 39.Sullivan GM, Feinn R. Using effect size: or why the p value is not enough. J Grad Med Educ. 2012;4(3):279–82.Google Scholar
- 40.Reich K, Segaert S, Van de Kerkhof P, Durian C, Boussuge MP, Paolozzi L, et al. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. Dermatology. 2009;219(3):239–49.Google Scholar
- 41.Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol. 2005;153(6):1192–9.Google Scholar
- 42.Nakagawa H, Schenkel B, Kato M, Kato T, Igarashi A. Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: results from a randomized, double-blind, placebo-controlled phase 2/3 trial. J Dermatol. 2012;39(9):761–9.Google Scholar
- 43.Igarashi A, Kato T, Kato M, Song M, Nakagawa H. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol. 2012;39(3):242–52. https://doi.org/10.1111/j.346-8138.2011.01347.x (Epub 2011 Sep 29).Google Scholar
- 44.Nakagawa H, Niiro H, Ootaki K. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016;81(1):44–52.Google Scholar
- 45.Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181–9.Google Scholar
- 46.Jankovic S, Raznatovic M, Marinkovic J, Jankovic J, Kocev N, Tomic-Spiric V, et al. Health-related quality of life in patients with psoriasis. J Cutan Med Surg. 2011;15(1):29–36.Google Scholar
- 47.Meijer JM, Meiners PM, Huddleston Slater JJ, Spijkervet FK, Kallenberg CG, Vissink A, et al. Health-related quality of life, employment and disability in patients with Sjogren’s syndrome. Rheumatology (Oxford). 2009;48(9):1077–82.Google Scholar
- 48.Hewlett S, Cockshott Z, Byron M, Kitchen K, Tipler S, Pope D, et al. Patients’ perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheumatol. 2005;53(5):697–702.Google Scholar
- 49.Norheim KB, Harboe E, Goransson LG, Omdal R. Interleukin-1 inhibition and fatigue in primary Sjogren’s syndrome: a double blind, randomised clinical trial. PLoS One. 2012;7(1):e30123.Google Scholar
- 50.Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, et al. A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31.e1–15.Google Scholar
- 51.Bachelez H, Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015;386(9993):552–61.Google Scholar
- 52.Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367–74.Google Scholar
- 53.Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55(4):598–606.Google Scholar
- 54.Reich KG, Foley P, Song M, Wasfi Y, Li S, Shen YK, Han C, Armstrong A. General health-related quality of life among plaque psoriasis patients treated with guselkumab or adalimumab: results from a phase 3 randomized clinical trial. In: 26th EADV Congress, 13–17 Sep 2017, Geneva.Google Scholar